Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Missed Opportunities on Emergency Remdesivir Use

Missed Opportunities on Emergency Remdesivir Use This Viewpoint argues that the FDA’s Emergency Use Authorization (EUA) of remdesivir missed important opportunities to mandate further study of the drug’s safety and efficacy and to require fair drug pricing, and proposes modifications to create a patient registry with required data entry for any prescription and to allow government negotiations to achieve a reasonable drug price based on shared risk-taking. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Missed Opportunities on Emergency Remdesivir Use

JAMA , Volume 324 (4) – Jul 28, 2020

Loading next page...
 
/lp/american-medical-association/missed-opportunities-on-emergency-remdesivir-use-CUPAaK1u11
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2020.11932
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint argues that the FDA’s Emergency Use Authorization (EUA) of remdesivir missed important opportunities to mandate further study of the drug’s safety and efficacy and to require fair drug pricing, and proposes modifications to create a patient registry with required data entry for any prescription and to allow government negotiations to achieve a reasonable drug price based on shared risk-taking.

Journal

JAMAAmerican Medical Association

Published: Jul 28, 2020

References